JP2019512251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512251A5 JP2019512251A5 JP2018549452A JP2018549452A JP2019512251A5 JP 2019512251 A5 JP2019512251 A5 JP 2019512251A5 JP 2018549452 A JP2018549452 A JP 2018549452A JP 2018549452 A JP2018549452 A JP 2018549452A JP 2019512251 A5 JP2019512251 A5 JP 2019512251A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- host cell
- amino acid
- nucleic acid
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023045262A JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU93006 | 2016-03-23 | ||
| LULU93006 | 2016-03-23 | ||
| PCT/EP2017/056931 WO2017162797A1 (en) | 2016-03-23 | 2017-03-23 | Fusion proteins of pd-1 and 4-1bb |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023045262A Division JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512251A JP2019512251A (ja) | 2019-05-16 |
| JP2019512251A5 true JP2019512251A5 (enExample) | 2019-09-19 |
| JP7250519B2 JP7250519B2 (ja) | 2023-04-03 |
Family
ID=55702054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549452A Active JP7250519B2 (ja) | 2016-03-23 | 2017-03-23 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
| JP2023045262A Active JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023045262A Active JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11365237B2 (enExample) |
| EP (2) | EP4286522A3 (enExample) |
| JP (2) | JP7250519B2 (enExample) |
| CN (1) | CN109195985B (enExample) |
| AU (1) | AU2017236069B2 (enExample) |
| CA (1) | CA3017036A1 (enExample) |
| ES (1) | ES2962588T3 (enExample) |
| WO (1) | WO2017162797A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180029201A (ko) | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| EP4286522A3 (en) * | 2016-03-23 | 2024-02-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| CA3038150A1 (en) * | 2016-12-22 | 2018-06-28 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
| WO2018181390A1 (ja) | 2017-03-31 | 2018-10-04 | 東亞合成株式会社 | Ｐｄ－１シグナル配列を有する抗腫瘍ペプチドおよびその利用 |
| SG11202013170RA (en) * | 2018-07-11 | 2021-01-28 | Kahr Medical Ltd | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102351041B1 (ko) * | 2018-12-19 | 2022-01-13 | 한국화학연구원 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| WO2020146423A1 (en) * | 2019-01-07 | 2020-07-16 | Thomas Jefferson University | Multi-functional fusion proteins and uses thereof |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| CN115956086A (zh) * | 2020-05-06 | 2023-04-11 | 萨摩亚商柏沛生医股份有限公司 | 用于针对癌症及传染病的免疫疗法的融合蛋白 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| WO2023025779A1 (en) * | 2021-08-25 | 2023-03-02 | Medigene Immunotherapies Gmbh | Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors |
| JP2025527657A (ja) * | 2022-08-23 | 2025-08-22 | メディジーン イミュノテラピーズ ゲーエムベーハー | Ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体とキメラ共刺激受容体との組み合わせ物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141520A1 (es) * | 2011-07-29 | 2014-11-17 | Univ Pennsylvania | Receptores coestimuladores de cambio |
| KR101471647B1 (ko) * | 2011-10-26 | 2014-12-11 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| CN105518018B (zh) * | 2013-03-15 | 2020-04-03 | 细胞基因公司 | 修饰的t淋巴细胞 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| BR112015027567B1 (pt) | 2013-05-03 | 2024-02-20 | Ohio State Innovation Foundation | Polipeptídeo, sequência de ácido nucleico isolada, vetor, método de obtenção de célula, uso de uma célula |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| SG10201900455YA (en) * | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| US20170209492A1 (en) * | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| CA2973529A1 (en) * | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| AU2015380397B2 (en) * | 2015-01-31 | 2021-10-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| CA2976684C (en) * | 2015-03-02 | 2024-03-05 | Innovative Cellular Therapeutics CO., LTD. | Reducing immune tolerance induced by pd-l1 |
| CN107531805A (zh) * | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| KR20180029201A (ko) * | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| CN104829733B (zh) | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
| PT3310805T (pt) * | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| HK1255637A1 (zh) * | 2015-06-29 | 2019-08-23 | The Johns Hopkins University | 免疫检查点嵌合受体疗法 |
| EP3344284A1 (en) * | 2015-09-04 | 2018-07-11 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| AU2017230011A1 (en) * | 2016-03-11 | 2018-09-27 | 2Seventy Bio, Inc. | Genome edited immune effector cells |
| EP4286522A3 (en) * | 2016-03-23 | 2024-02-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| WO2019169290A1 (en) * | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| EP3774906A1 (en) * | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
-
2017
- 2017-03-23 EP EP23193951.3A patent/EP4286522A3/en active Pending
- 2017-03-23 US US16/087,262 patent/US11365237B2/en active Active
- 2017-03-23 WO PCT/EP2017/056931 patent/WO2017162797A1/en not_active Ceased
- 2017-03-23 EP EP17713250.3A patent/EP3433269B1/en active Active
- 2017-03-23 AU AU2017236069A patent/AU2017236069B2/en active Active
- 2017-03-23 JP JP2018549452A patent/JP7250519B2/ja active Active
- 2017-03-23 ES ES17713250T patent/ES2962588T3/es active Active
- 2017-03-23 CN CN201780031958.9A patent/CN109195985B/zh active Active
- 2017-03-23 CA CA3017036A patent/CA3017036A1/en active Pending
-
2022
- 2022-06-08 US US17/835,936 patent/US20220380435A1/en active Pending
-
2023
- 2023-03-22 JP JP2023045262A patent/JP7746323B2/ja active Active
- 2023-11-16 US US18/510,940 patent/US20240247046A1/en active Pending